BIO Bionostics

RNS Number:0860Y
Bionostics PLC
08 June 2007


FOR IMMEDIATE RELEASE                                                8 June 2007

                                 Bionostics PLC
                        ("Bionostics" or "the Company")

                    Statement regarding share price movement


The Board of Bionostics notes the recent rise in the Company's share price and
confirms that it is in discussions with a party which may or may not lead to an
offer being made for the Company. There is no certainty that any offer will be
forthcoming.

Further announcements will be made as appropriate.

Dealing Disclosure Requirements

Under the provisions of Rule 8.3 of the Takeover Code (the "Code"), if any
person is, or becomes, "interested" (directly or indirectly) in 1% or more of
any class of "relevant securities" of Bionostics PLC, all dealings in any
"relevant securities" of that company (including by means of an option in
respect of, or a derivative referenced to, any such "relevant securities") must
be publicly disclosed by no later than 3:30 pm (London time) on the London
business day following the date of the relevant transaction. This requirement
will continue until the date on which the offer becomes, or is declared,
unconditional as to acceptances, lapses or is otherwise withdrawn or on which
the "offer period" otherwise ends. If two or more persons act together pursuant
to an agreement or understanding, whether formal or informal, to acquire an
"interest" in "relevant securities" of Bionostics PLC, they will be deemed to be
a single person for the purpose of Rule 8.3.

Under the provisions of Rule 8.1 of the Code, all "dealings" in "relevant
securities" of Bionostics PLC by the potential offeror, Bionostics PLC or by any
of their respective "associates", must be disclosed by no later than 12:00 noon
(London time) on the London business day following the date of the relevant
transaction.

A disclosure table, giving details of the companies in whose "relevant
securities" "dealings" should be disclosed, and the number of such securities in
issue, can be found on the Takeover Panel's website at
www.thetakeoverpanel.org.uk.

"Interests in securities" arise, in summary, when a person has long economic
exposure, whether conditional or absolute, to changes in the price of
securities. In particular, a person will be treated as having an "interest" by
virtue of the ownership or control of securities, or by virtue of any option in
respect of, or derivative referenced to, securities.

Terms in quotation marks are defined in the Code, which can also be found on the
Panel's website. If you are in any doubt as to whether or not you are required
to disclose a "dealing" under Rule 8, you should consult the Panel.

                                    - Ends -

Enquiries:

Bionostics PLC

Paul Haycock, Chairman                                             01993 885 070
Kelly Winn, Finance Director

Weber Shandwick Financial                                          020 7067 0700
Nick Oborne/Helen Thomas/Charlie Hooper



                      This information is provided by RNS
            The company news service from the London Stock Exchange

END
SPMILFFDRTITIID

Grafico Azioni Biofocus (LSE:BIO)
Storico
Da Mag 2024 a Giu 2024

Grafico Azioni Biofocus (LSE:BIO)
Storico
Da Giu 2023 a Giu 2024